Welcome!

News Feed Item

RNAi for Therapeutic Applications: Technology and Market 2014-2024

LONDON, February 20, 2014 /PRNewswire/ --

Potential of RNAi therapies - new analysis showing R&D, trends, and revenue prospects

Where are RNA interference based medicines going? For those treatments you can get new sales predictions and explore developments. You unlock that emerging medical industry. And you assess its results, trends, technologies, potentials, and opportunities.

Visiongain's new report forecasts those revenues to 2024 at overall world market, product, and national level. Discover now what's happening. You stay ahead in data, then, helping your influence. Hear about potential gains for companies pioneering those drugs.

Forecasts to 2024 and other analyses predict and explain the RNAi-based drug market

Why miss data you need? Why struggle to find it? Instead our report gives you revenue forecasts to 2024, also with historical data, growth rates, and market shares.

Also you investigate research and development, assessing its potential. The study also gives 59 tables, 26 charts, and interviews with two companies.

Prospects for that technology - analyses showing where the money lies

The new report shows the lucrative opportunities for ribonucleic acid interference (RNAi) technologies. And you discover forecasting for both optimistic and conservative scenarios. Those analyses predict how much money the pharma industry can earn.

See how that original analysis can benefit your reputation for commercial insight.

And the following sections explain what our investigation gives to help your research, analyses, and decisions.

Sales predictions for that world market and its products

What secrets influence RNAi medicine's future? Once companies overcome technological challenges - gaining regulatory approval - patients will benefit. Discover in our report overall world revenue estimates to 2024 with discussions of trends and prospects.

Also you find individual revenue forecasts to 2024 for 11 therapeutic agents, including these:
• PF-655
• QPI-1007
• SYL040012
• ALN-RSV01
• ARC-520
• SPC3649 (Miravirsen).

There you assess advances and outlooks for those biopharmaceuticals. Hear where you could profit.

Where lie the best prospects? There you explore outlooks for sales, assessing where revenues and profits lie. Find data on gene silencing and its business potential.

For that biotechnology, our work also shows you geographical revenue predictions.

To see an exec summary of this report please email Sara Peerun on [email protected]

National markets - what outlooks to 2024 for RNAi drug revenues?

Advances in science, biotechnology and pharma expand possibilities of medicines harnessing RNAi interference. You gain feel for those technologies' revenue prospects.

So our analyses give you individual revenue forecasts to 2024 for 11 national markets:
United States (US)
Japan
• EU leaders - Germany, France, the UK, Italy, and Spain (EU5)
• BRIC nations - Brazil, Russia, India, and China.

There you find regions with highest revenues, demand, and potential sales growth. Our work explains. You see international prospects.

Explore, too, how RNAi technology can benefit its developers, producers, marketers, and sellers. Our work shows you, also discussing technological progress and its meaning.

Developing products - discover trends, innovations, and progress

You also investigate R&D, finding technological and commercial possibilities. Our report discusses these advances and others:
• Short or small interfering RNA (siRNA)
• Expressed/DNA-directed RNAi (ddRNAi)
• Locked nucleic acid (LNA) and short hairpin RNA (shRNA), inc. viral vectors
• microRNA (miRNA) - natural gene expression regulators
• Novel drug delivery, including nanoparticle-based systems.

And it explores applications such as these:
• Ocular disorders, inc. age-related macular degeneration (AMD) and glaucoma
• Lung conditions, inc. respiratory syncytial virus (RSV) infection
• Infectious diseases, inc. hepatitis B and C virus (HBV and HCV) infections
• Kidney disease, inc. delayed graft function (DGF)
• Cancers - advantages in oncology.

Despite difficulties, pre-clinical and clinical developments there hold strength, variety, and promise. See what's possible for big pharma and specialists in biological drugs (biologics).

And what events change that industry? Our work shows you, discussing trends and needs.

Developments, challenges, and effects influencing RNAi technologies

The report explains forces affecting that industry and market from 2014, including these:
• Reducing side effects, including adverse immune reactions
• Orphan drug designation for competitive advantages
• Personalised therapy, inc. targeting multiple cancer subtypes
• Prospects for combination therapy
• Strategic alliances, out-licensing technology, and contract manufacturing.

What happens next? There discover what the present and future hold. You examine what encourages and restrains players in that sector, and affects its results.

To see an exec summary of this report please email Sara Peerun on [email protected]

Analysis of companies leading that biotechnological field

From this decade, technological developments and needs of patients, doctors, and payers will encourage investments, medical advances, and sales of RNAi-based therapeutics.

And there you examine activities of many organisations, including these:
• Alnylam Pharmaceuticals
• Silence Therapeutics
• RXi Pharmaceuticals
• Quark Pharmaceuticals
• Santaris Pharma.

You find 119 organisations covered in the study. You also get interviews with authorities in that industry. Discover what participants do, say, and think.

Ways RNAi for Therapeutic Applications: Technology and Market 2014-2024 helps

In particular, our new investigation gives this knowledge to help your work:
• Revenues there to 2024 at world level and for 11 expected products - assess outlooks for approvals, production, marketing, and sales
• Forecasts to 2024 for 11 national markets in the Americas, Europe, and Asia - explore developed and developing countries for future revenues
• Activities of companies in that biomedical field - investigate technologies, R&D pipelines, drug candidates, strategies, and prospects.

Data found nowhere else, helping your searches, analyses, and plans

Our study gives independent analysis. There you receive competitive intelligence found only in our work, finding where progress and money lie. You explore commercial outlooks.

So with our findings you're less likely to miss opportunity. Being free to choose, then, our study shows how you could save time and effort, also helping planning, decisions, and influence.

This new report is for everyone analysing emerging technologies in biopharma. For RNAi-based medicines you explore R&D trends, issues, and sales predictions. Avoid missing out, then - please order now.

To request an exec summary of this report please email Sara Peerun at           [email protected] or call Tel : +44 (0) 20 7336 6100

Or click on http://www.visiongain.com/Report/1204/RNAi-for-Therapeutic-Applications-Technology-and-Market-2014-2024

Companies Listed

Acuity Pharmaceuticals
Aegera Therapeutics
Agilent Technologies
Alcon
Allele Biotechnology
Allergan
Alnylam Pharmaceuticals
Altogen Labs
Antisense Therapeutics
Antisoma Research
Archemix Corporation
ArmaGen Technologies
Arrowhead Research Corporation
Ascletis Pharmaceuticals
AstraZeneca
Atlantic Pharmaceuticals
Atugen AG
Avecia OligoMedicines
AVI BioPharma
Bayer
Bio Synthesis
Biocon
Biogen Idec
Biomatik Corporation
Biomics Biotechnologies
Bionexus
BioSpring
Bristol-Myers Squibb
Calando Pharmaceuticals
Carnegie Institution for Science
Chinese University of Hong Kong
Cubist Pharmaceuticals
Dainippon Sumitomo Pharma
Dharmacon RNAi Technologies
Eleos
Eli Lilly
Enzo Therapeutics
Enzon Pharmaceuticals
Eurofins MWG-Biotech
Eurogentec
European Commission
European Medicines Agency (EMA)
European Union (EU)
Expression Genetics
Eyetech Pharmaceuticals
EZBiolab
Food and Drug Administration (US FDA)
Gene Link
Gene Signal International
GeneCare Research Institute
GeneDesign
Genentech
Genta Incorporated
Genzyme
Girindus America
Gradalis
GlaxoSmithKline (GSK)
Halo-Bio RNAi Therapeutics
Integrated DNA Technologies
Intradigm Corporation
Invitrogen
Isarna Therapeutics
ISIS Pharmaceuticals
Kyowa Hakko Kirin
Life Technologies
Lorus Therapeutics
Marina Biotech
Mary Crowley Cancer Research Centre
Max Planck Institute
MedImmune
Medtronic
Merck & Co.
Merz Pharmaceuticals
Nitto Denko Corporation
Novartis
NovaRx Corporation
Novosom
Noxxon Pharma
Ohio State University (OSU)
Oligoengine
OncoGenex Technologies
Ophthotech Corporation
OPKO Health
OSI Pharmaceuticals
Pfizer
Protiva Biotherapeutics
Qiagen
Quark Biotech
Quark Pharmaceuticals
Regado Biosciences
Regeneron Pharmaceuticals
Ribopharma AG
RiboTask
RXi Pharmaceuticals
Roche
SABiosciences
Samyang Corporation
Santaris Pharma
Sanofi
Shire
Sigma Aldrich
Silence Therapeutics
Sirnaomics
Sirna Therapeutics
Spanish Society for Glaucoma
Solvay Group
Suzhou Ribo Life Sciences
Sylentis
Talon Pharmaceuticals
Takeda
Targeted Genetics Corporation
Tekmira Pharmaceuticals
Teva Pharmaceuticals
The Medicines Company
Thermo Scientific
Traversa Therapeutics
University of Bayreuth
University of Massachusetts Medical School
VIRxSYS
World Health Organization (WHO)
Zeltia Group

To see an exec summary of this report please email Sara Peerun on [email protected]

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
With major technology companies and startups seriously embracing IoT strategies, now is the perfect time to attend @ThingsExpo 2016 in New York. Learn what is going on, contribute to the discussions, and ensure that your enterprise is as "IoT-Ready" as it can be! Internet of @ThingsExpo, taking place June 6-8, 2017, at the Javits Center in New York City, New York, is co-located with 20th Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry p...
All organizations that did not originate this moment have a pre-existing culture as well as legacy technology and processes that can be more or less amenable to DevOps implementation. That organizational culture is influenced by the personalities and management styles of Executive Management, the wider culture in which the organization is situated, and the personalities of key team members at all levels of the organization. This culture and entrenched interests usually throw a wrench in the work...
Judith Hurwitz is president and CEO of Hurwitz & Associates, a Needham, Mass., research and consulting firm focused on emerging technology, including big data, cognitive computing and governance. She is co-author of the book Cognitive Computing and Big Data Analytics, published in 2015. Her Cloud Expo session, "What Is the Business Imperative for Cognitive Computing?" is scheduled for Wednesday, June 8, at 8:40 a.m. In it, she puts cognitive computing into perspective with its value to the busin...
NHK, Japan Broadcasting, will feature the upcoming @ThingsExpo Silicon Valley in a special 'Internet of Things' and smart technology documentary that will be filmed on the expo floor between November 3 to 5, 2015, in Santa Clara. NHK is the sole public TV network in Japan equivalent to the BBC in the UK and the largest in Asia with many award-winning science and technology programs. Japanese TV is producing a documentary about IoT and Smart technology and will be covering @ThingsExpo Silicon Val...
SYS-CON Events announced today that CollabNet, a global leader in enterprise software development, release automation and DevOps solutions, will be a Bronze Sponsor of SYS-CON's 20th International Cloud Expo®, taking place from June 6-8, 2017, at the Javits Center in New York City, NY. CollabNet offers a broad range of solutions with the mission of helping modern organizations deliver quality software at speed. The company’s latest innovation, the DevOps Lifecycle Manager (DLM), supports Value S...
The 20th International Cloud Expo has announced that its Call for Papers is open. Cloud Expo, to be held June 6-8, 2017, at the Javits Center in New York City, brings together Cloud Computing, Big Data, Internet of Things, DevOps, Containers, Microservices and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding business opportunity. Submit your speaking proposal ...
Building a cross-cloud operational model can be a daunting task. Per-cloud silos are not the answer, but neither is a fully generic abstraction plane that strips out capabilities unique to a particular provider. In his session at 20th Cloud Expo, Chris Wolf, VP & Chief Technology Officer, Global Field & Industry at VMware, will discuss how successful organizations approach cloud operations and management, with insights into where operations should be centralized and when it’s best to decentraliz...
The age of Digital Disruption is evolving into the next era – Digital Cohesion, an age in which applications securely self-assemble and deliver predictive services that continuously adapt to user behavior. Information from devices, sensors and applications around us will drive services seamlessly across mobile and fixed devices/infrastructure. This evolution is happening now in software defined services and secure networking. Four key drivers – Performance, Economics, Interoperability and Trust ...
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm. In his Day 3 Keynote at 20th Cloud Expo, Chris Brown, a Solutions Marketing Manager at Nutanix, will explore t...
With billions of sensors deployed worldwide, the amount of machine-generated data will soon exceed what our networks can handle. But consumers and businesses will expect seamless experiences and real-time responsiveness. What does this mean for IoT devices and the infrastructure that supports them? More of the data will need to be handled at - or closer to - the devices themselves.
@DevOpsSummit at Cloud taking place June 6-8, 2017, at Javits Center, New York City, is co-located with the 20th International Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to wait for long developm...
Cloud Expo, Inc. has announced today that Aruna Ravichandran, vice president of DevOps Product and Solutions Marketing at CA Technologies, has been named co-conference chair of DevOps at Cloud Expo 2017. The @DevOpsSummit at Cloud Expo New York will take place on June 6-8, 2017, at the Javits Center in New York City, New York, and @DevOpsSummit at Cloud Expo Silicon Valley will take place Oct. 31-Nov. 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
Translating agile methodology into real-world best practices within the modern software factory has driven widespread DevOps adoption, yet much work remains to expand workflows and tooling across the enterprise. As models evolve from pockets of experimentation into wholescale organizational reinvention, practitioners find themselves challenged to incorporate the culture and architecture necessary to support DevOps at scale. In his session at @DevOpsSummit at 20th Cloud Expo, Anand Akela, Senior...
In his keynote at @ThingsExpo, Chris Matthieu, Director of IoT Engineering at Citrix and co-founder and CTO of Octoblu, focused on building an IoT platform and company. He provided a behind-the-scenes look at Octoblu’s platform, business, and pivots along the way (including the Citrix acquisition of Octoblu).
Grape Up is a software company, specialized in cloud native application development and professional services related to Cloud Foundry PaaS. With five expert teams that operate in various sectors of the market across the USA and Europe, we work with a variety of customers from emerging startups to Fortune 1000 companies.